Skip to content
Bamboo Works
Search
Sign in / Register
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • Infrastructure/Resources
  • Fast News
  • Focus Companies
    • 360 DigiTech
    • Atrenew
    • Beigene
    • Cango
    • Daqo New Energy
    • Huazhu
    • Pop Mart
    • Tuya
    • Yalla
    • Yum China
  • Expert Corner
  • Premium Content
  • China ESG Focus
  • About Us
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • Infrastructure/Resources
  • Fast News
  • Focus Companies
    • 360 DigiTech
    • Atrenew
    • Beigene
    • Cango
    • Daqo New Energy
    • Huazhu
    • Pop Mart
    • Tuya
    • Yalla
    • Yum China
  • Expert Corner
  • Premium Content
  • China ESG Focus
  • About Us
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Johnson & Johnson

Legend Biotech announced Tuesday its second quarter revenue jumped 513% year-on-year to $73.33 million, mainly due to higher revenue from the sale of Carvykti, a product in collaboration with Janssen Biotech.

FAST NEWS: Legend Biotech’s revenue soars, but fails to turnaround losses

The latest: Legend Biotech Corp. (LEGN.US) announced Tuesday its second quarter revenue jumped 513% year-on-year to $73.33 million, mainly due to higher revenue from the sale of Carvykti, a product in collaboration…
August 16, 2023
LEGN.US

FAST NEWS: Legend Biotech shares jump on rising cancer drug sales

The latest: Cell therapy company Legend Biotech Corp. (LEGN.US) recorded net sales of $117 million in the second quarter for its Carvykti cancer drug, up 65% from the previous quarter, according to…
July 21, 2023
LEGN.US

FAST NEWS: Legend Biotech to raise $300 million from share sale

The latest: Genscript Biotech Corp. (1548.HK) announced Monday that its New York-listed subsidiary Legend Biotech Corp. (LEGN.US) will sell about 5.5 million new American Depositary Shares (ADSs) to an entity advised by…
May 8, 2023
LEGN.US 1548.HK

FAST NEWS: Legend Biotech cancer drug posts strong first-quarter sales

The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), announced Tuesday it recorded net sales of approximately $72 million in the first quarter for its Carvykti cancer…
April 19, 2023
LEGN.US

Genscript Bio Gets Booster from Subsidiary’s New Cancer Drug

The company’s Legend Biotech unit has found recent success with Carvykti, a chimeric antigen receptor T-cell (CAR-T) therapy, which earned $134 million in its first nine months on the marketKey…
February 2, 2023

InnoCare Revs Up for Next Phase With Strong Results, IPO Plan

Sales of the company’s key Orelabrutinib cancer drug doubled in the first half of the year, contributing to a 142% revenue jump for the period Key Takeaways: InnoCare Pharma’s revenue…
August 29, 2022

With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors

The biotechnology company, which is facing ballooning losses without any revenue like many of its peers, has filed for an IPO in Hong Kong (more…)
June 24, 2022

Recent Articles

Legend Biotech announced Tuesday its second quarter revenue jumped 513% year-on-year to $73.33 million, mainly due to higher revenue from the sale of Carvykti, a product in collaboration with Janssen Biotech.
August 16, 2023

FAST NEWS: Legend Biotech’s revenue soars, but fails to turnaround losses

LEGN.US
July 21, 2023

FAST NEWS: Legend Biotech shares jump on rising cancer drug sales

LEGN.US
May 8, 2023

FAST NEWS: Legend Biotech to raise $300 million from share sale

LEGN.US 1548.HK
April 19, 2023

FAST NEWS: Legend Biotech cancer drug posts strong first-quarter sales

LEGN.US
February 2, 2023

Genscript Bio Gets Booster from Subsidiary’s New Cancer Drug

August 29, 2022

InnoCare Revs Up for Next Phase With Strong Results, IPO Plan

June 24, 2022

With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors

Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

Bamboo Works offers a range of partnerships for corporate and other partners, including opportunities for sponsored content, article-writing services and a wide range of promotions.

About Us
Focus Companies
Fast News
Expert Corner
Premium Content
Facebook Twitter Linkedin Weixin Weibo File-alt

Categories

  • Ecommerce
  • Healthcare/biotech
  • New Energy
  • IPO
  • Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer

Newsletter

For all latest news, offers and special announcements.
Subscribe
Copyright © 2022 Bamboo Works. All rights reserved.